Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Tseng IJ
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=None
------>paper_class3=1
------>paper_class2=3
------>vol=
------>confirm_bywho=ryyuan
------>insert_bywho=ryyuan
------>Jurnal_Rank=None
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=
------>medlineContent=
------>unit=E0123
------>insert_date=20080508
------>iam=2
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=444
------>journal_name=
------>paper_name=Elevated Plasma Homocysteine Levels in L-dopa Treated Parkinson's Disease Patients with Dementia.???????????????????????
------>confirm_date=20081203
------>tch_id=073009
------>pmid=16776634
------>page1=
------>fullAbstract=BACKGROUND: Elevated plasma homocysteine (Hcy) concentrations are associated with increased risk of systemic vascular diseases, Alzheimer~s disease and vascular dementia. Several cross-sectional reports and two prospective clinical studies have recently reported elevated plasma Hcy levels in L-dopa-treated Parkinson~s disease (PD) patients and Hcy has been proposed as a possible mediator for the development of long-term L-dopa motor complications (such as wearing off and on-off phenomena, and dyskinesias). The aim of the study was to elucidate a possible role of L-dopa-related hyperhomocysteinemia in the development of dyskinesias. METHODS: In this cross-sectional study we compared Hcy, B(12) and folate levels in 53 PD patients treated with L-dopa (29 with dyskinesias, 24 without dyskinesias). RESULTS: Mean plasma Hcy levels were higher in the group of PD patients with dyskinesias (19 vs. 15.4 micromol/L; T: 2.12; p=0.04). After taking into account potential confounding factors, analysis of the data revealed that the occurrence of dyskinesias progressively increased with plasma Hcy levels (relative risk 1.2, 95% CI 1.015-1.4; p=0.03). CONCLUSIONS: Our results raise the possibility that Hcy plays a role in the development of dyskinesias, through its toxic effects on both dopaminergic neurons and non-substantia nigra, non-dopaminergic neurons.
------>tmu_sno=None
------>sno=18570
------>authors2=Yuan RY
------>authors3=Hung YL
------>authors4=Lo PN
------>authors5=
------>authors6=
------>authors6_c=
------>authors=Tseng IJ
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Elevated plasma homocysteine levels in L-dopa-treated Parkinson~s disease patients with dyskinesias.
------>language=1
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2006
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z